Joby Aviation, Inc. (NYSE: JOBY) is presenting a more expansive investment narrative than the familiar electric-air-taxi story. Its autonomous J208 program, a Cessna 208B Grand Caravan fitted with Joby’s Superpilot autonomy system, is a practical attempt to make regional cargo, emergency response…
The one-off Bugatti La Voiture Noire is more than a hypercar with a spectacular price tag. It is a rolling argument for ultra-luxury’s most durable formula: heritage, technical theater, and the rarest commodity of all, something no one else can buy.
For…
Sydney Sweeney may not have intended to become the face of financial-market infrastructure, but her headline-grabbing campaign for sports prediction platform Novig has put the fast-growing event-contract business squarely in the mainstream conversation. For many, the more consequential beneficiary may be…
Oracle Corporation (NYSE: ORCL) has spent decades selling the corporate plumbing that keeps global business running. Now, it is turning that unglamorous-but-essential heritage into a far more fashionable enterprise: a major supplier of artificial-intelligence computing capacity. The latest quarter suggests Oracle’s AI…
Koenigsegg’s new CCGT1 is more than a 1,600-horsepower Swedish hypercar. It is a sharp reminder that, at the summit of the luxury-performance market, scarcity, engineering credibility and a compelling origin story can create demand that is already spoken for before the public…
Knightscope (NASDAQ: KSCP) is pursuing a bigger prize than selling robots: it is assembling an integrated, technology-enabled security service designed to combine autonomous machines, AI software, remote monitoring and licensed human agents under one accountable operating model.
There is no shortage of…
Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received…
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has moved up to the Nasdaq Global Select Market just as its lead clinical program approaches a pivotal Phase 2b interim data event. For many, the timing is rather tidy: the company is pairing greater market…
NVIDIA Corp. (NASDAQ: NVDA) has spent the past several years selling the shovels for the artificial-intelligence gold rush. Its planned $12.93 billion acquisition of Hugging Face suggests it now wants a more influential place in the mine, the marketplace and perhaps the…
Modular Medical, Inc. (NASDAQ: MODD) is moving from a development-stage story toward the far more interesting phase of the medical-device lifecycle: selling an FDA-cleared product into a defined market with a deliberately measured commercialization plan. Its upcoming Pivot™ tubeless insulin patch pump rollout…
